The Health Ministry has announced the latest list of reimbursed drugs, which will take effect on April 1. It includes 29 new therapies, including 10 designed for oncology patients. The cutting-edge treatments will be available for lung, breast, ovarian and prostate cancer, among others, meaning a better chance of effective therapy and a longer life for many patients.
New cancer therapies in reimbursement
The updated reimbursement list will include durvalumab, tremelimumab and alectinib - drugs used in the treatment of lung cancer and pleural mesothelioma. In particular, alectinib, as an ALK tyrosine kinase inhibitor, opens up new therapeutic options for patients with non-small cell lung cancer diagnosed with ALK gene rearrangement. Its use after radical surgical treatment significantly reduces the risk of disease recurrence.
Lung cancer - new treatment options
Prof. Dariusz M. Kowalski, MD, head of the Behavioral Unit of the Lung and Chest Cancer Clinic at the N...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at english@medexpress.pl.
If you already have an account, please log in
